Table A3.
Multivariable Cox Proportional Hazards Model Among All Patients Using Age As a Continuous Variable
| Parameter | Relapse-Free Survival |
Overall Survival |
||||
|---|---|---|---|---|---|---|
| Hazard Ratio | 95% CI | P | Hazard Ratio | 95% CI | P | |
| Beta-blocker use, yesvno | 0.54 | 0.32 to 0.91 | .021 | 0.65 | 0.39 to 1.08 | .10 |
| Age (continuous) | 0.98 | 0.97 to 0.99 | .003 | 1.00 | 0.99 to 1.01 | .98 |
| Race, Blackv non-black | 1.38 | 1.06 to 1.78 | .015 | 1.48 | 1.13 to 1.93 | .004 |
| Stage, IIIv I/II | 1.69 | 1.38 to 2.08 | < .001 | 1.78 | 1.43 to 2.21 | < .001 |
| Grade, IIIv I/II | 1.18 | 0.92 to 1.51 | .19 | 1.35 | 1.03 to 1.78 | .03 |
| Hormone receptor status, positivev negative | 0.75 | 0.49 to 1.14 | .18 | 0.76 | 0.47 to 1.23 | .26 |
| HER2 status, positivev negative | 1.31 | 0.92 to 1.87 | .13 | 1.02 | 0.69 to 1.52 | .91 |
| Triple-negative tumor, yesv no | 1.40 | 0.87 to 2.26 | .17 | 1.62 | 0.95 to 2.77 | .08 |
| LVI, positivev negative | 1.85 | 1.5 to 2.28 | < .001 | 1.70 | 1.35 to 2.13 | < .001 |
| BMI, kg/m2 | ||||||
| 25-29v < 25 | 1.01 | 0.78 to 1.31 | .94 | 1.03 | 0.78 to 1.37 | .81 |
| 30+v < 25 | 1.14 | 0.89 to 1.48 | .3 | 1.23 | 0.93 to 1.61 | .14 |
| Diabetes, yesv no | 1.24 | 0.79 to 1.94 | .34 | 1.64 | 1.08 to 2.5 | .021 |
| Hypertension, yesv no | 1.12 | 0.83 to 1.5 | .46 | 1.01 | 0.74 to 1.39 | .94 |
| ACEI/ARB use, yesv no | 0.85 | 0.55 to 1.3 | .44 | 0.99 | 0.65 to 1.51 | .96 |
Abbreviations: HER2, human epidermal growth factor receptor 2; LVI, lymphovascular invasion; BMI, body mass index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.